Free Trial

Prenetics Global (PRE) Stock Price, News & Analysis

-0.39 (-6.83%)
(As of 07/19/2024 ET)
Today's Range
50-Day Range
52-Week Range
6,727 shs
Average Volume
74,359 shs
Market Capitalization
$48.62 million
P/E Ratio
Dividend Yield
Price Target

Prenetics Global MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
68.2% Upside
$9.00 Price Target
Short Interest
0.38% of Float Sold Short
Dividend Strength
News Sentiment
0.92mentions of Prenetics Global in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.56 out of 5 stars

Medical Sector

461st out of 896 stocks

Analytical Instruments Industry

14th out of 26 stocks

PRE stock logo

About Prenetics Global Stock (NASDAQ:PRE)

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

PRE Stock Price History

PRE Stock News Headlines

Apple shares smash all-time highs…. but what’s next?
Over the past 40 years, Apple’s been at the forefront of tech with their computers, iPods, iTunes, iPhones and iPads. But the company seems poised to make an even bigger bet on artificial intelligence while it trades at all-time highs over $200. Most traders will wait for the price to dip before trying to sell higher… While others will simply short it as many believe the company’s overvalued. But there’s a THIRD way to trade Apple that most traders will miss.
Prenetics Flat on Financial Results
Biden Pushing To Replace The Dollar With a Digital Coin, Control Currency.
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
Prenetics Global: Q4 Earnings Insights
Prenetics Global (PRE) Earnings Dates & Reports
PRENW Prenetics Global Limited WT EXP 051827
Prenetics Global Stock (NASDAQ:PRE) Insider Trades
See More Headlines
Receive PRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$21.74 million
Book Value
$23.00 per share


Free Float
Market Cap
$48.90 million
Not Optionable
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Sheng Wu Yeung (Age 45)
    Co-Founder, Chairperson & CEO
  • Dr. Chi Hung Tzang Ph.D. (Age 49)
    Co-Founder, Chief Scientific Officer & Member of Scientific Advisory Board
  • Mr. Hoi Chun Lo (Age 39)
    Chief Financial Officer
  • Dr. Yung Ho Wong DPHIL (Age 42)
    Chief Technology Officer
  • Ms. Samantha Kwok
    Chief of Staff to Group CEO & Vice President, People & Operations
  • Dr. Senthil Sundaram M.D. (Age 50)
    Chief Clinical Officer
  • Mr. Joel Neoh (Age 40)
    Chief Consumer Officer & Chief Executive Officer for CircleDNA
  • Mr. Walt Ling
    Chief Executive Officer of ACT Genomics

PRE Stock Analysis - Frequently Asked Questions

How have PRE shares performed this year?

Prenetics Global's stock was trading at $5.91 at the beginning of the year. Since then, PRE shares have decreased by 9.5% and is now trading at $5.35.
View the best growth stocks for 2024 here

How were Prenetics Global's earnings last quarter?

Prenetics Global Limited (NASDAQ:PRE) issued its earnings results on Tuesday, June, 18th. The company reported ($0.38) EPS for the quarter. The firm earned $6.41 million during the quarter. Prenetics Global had a negative trailing twelve-month return on equity of 10.76% and a negative net margin of 282.96%.

When did Prenetics Global's stock split?

Prenetics Global shares reverse split before market open on Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Prenetics Global?

Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PRE) was last updated on 7/19/2024 by Staff

From Our Partners